Oxis Turbuhaler (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate, the active ingredient in Oxis Turbuhaler, is a long‑acting β‑adrenergic agonist (LABA) presented as a dry‑powder inhalation formulation for oral inhalation use. It provides bronchodilation for maintenance therapy in asthma and chronic obstructive pulmonary disease (COPD) in adults. GNH USA supplies Oxis Turbuhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oxis Turbuhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Formoterol fumarate is a bronchodilator that acts on the airway smooth‑muscle pathway to improve airflow.

- Asthma: improves lung function and reduces symptoms when used regularly as maintenance therapy. - Chronic obstructive pulmonary disease (COPD): provides sustained bronchodilation to ease breathing and reduce exacerbations. - Exercise‑induced bronchoconstriction: helps prevent airway narrowing during physical activity when combined with a rapid‑onset reliever.

Formoterol fumarate may cause adverse reactions, most of which are mild to moderate in intensity.

Common Side Effects: - Tremor: mild shaking of the hands. - Headache: occasional mild to moderate headache. - Throat irritation: dry or sore throat after inhalation. - Cough: transient coughing following dose administration. - Palpitations: sensation of rapid or irregular heartbeat.

Serious or Rare Side Effects: - Paradoxical bronchospasm: worsening airway narrowing after inhalation. - Cardiovascular events: arrhythmia, tachycardia, or angina in susceptible individuals. - Hypokalemia: low blood potassium levels, potentially causing muscle weakness. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Hyperglycaemia: elevated blood glucose, particularly in diabetic patients.

When prescribing Oxis Turbuhaler, clinicians should consider patient‑specific factors and follow standard safety measures.

- Assess asthma or COPD severity: confirm that maintenance therapy with a LABA is appropriate. - Review cardiovascular history: evaluate risk of tachycardia or arrhythmias. - Monitor for paradoxical bronchospasm: advise patients to seek immediate care if breathing worsens after use. - Use with inhaled corticosteroid: LABA therapy should be combined with an anti‑inflammatory controller. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

The safety profile ​         …  

Major  

    ext{ }}

    ewline   ewline

    ef  \\